Global Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Size

• The global jansen’s metaphyseal chondrodysplasia (JMC) market size was valued at USD 4.00 Million in 2024 and is expected to reach USD 5.73 Million by 2032, at a CAGR of 4.60% during the forecast period
• The market growth is largely fueled by the growing adoption and technological progress within connected home devices and smart home technology, leading to increased digitalization in both residential and commercial settings
• Furthermore, rising consumer demand for secure, user-friendly, and integrated solutions for their homes and businesses is establishing smart locks as the modern access control system of choice. These converging factors are accelerating the uptake of Jansen’s Metaphyseal Chondrodysplasia (JMC) solutions, thereby significantly boosting the industry's growth

Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Analysis

• Jansen’s Metaphyseal Chondrodysplasia (JMC) treatments are gaining importance in healthcare due to their role in managing rare skeletal disorders, improving patient outcomes, and supporting long-term quality of life
• The increasing demand for JMC therapies is driven by growing awareness of the disease, advancements in targeted treatments, and the need for accessible and effective solutions for patients across various regions
• North America dominated the Jansen’s Metaphyseal Chondrodysplasia (JMC) market with the largest revenue share of 42% in 2024, supported by advanced healthcare infrastructure, high healthcare spending, and the presence of leading pharmaceutical companies specializing in rare disease therapies. The U.S. remains the primary contributor, with strong growth in the development and deployment of new treatment protocols and patient support programs for JMC
• Asia-Pacific is expected to be the fastest-growing region in the Jansen’s Metaphyseal Chondrodysplasia (JMC) market during the forecast period, driven by increasing healthcare awareness, expanding healthcare infrastructure, and rising investments in rare disease treatment programs. Countries such as India, China, and Southeast Asian nations are witnessing growth in patient access to specialized therapies and clinical trial participation, accelerating market adoption
• The Surgery segment dominated the largest market revenue share of 58.4% in 2024, owing to the high incidence of skeletal deformities requiring corrective procedures. Hospitals and specialty clinics implement standardized surgical protocols to restore mobility and function

Report Scope and Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Segmentation    

Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Trends

Advancements in Targeted Therapies and Genetic Research

• A significant trend in the global JMC market is the increasing focus on the development of targeted therapies and precision medicine approaches that directly address the genetic mutations responsible for the disease
  • For instance, researchers are exploring small-molecule inhibitors and monoclonal antibodies that can specifically target pathways involved in abnormal bone growth and skeletal deformities associated with JMC
• Gene-editing technologies, such as CRISPR-Cas9, are also gaining attention for their potential to correct the underlying mutations in preclinical studies, offering hope for long-term disease management
• The growing availability of patient registries and genetic databases is enabling better understanding of the disease progression, treatment response, and patient stratification for clinical trials
• Collaboration between academic institutions, biotechnology companies, and pharmaceutical firms is accelerating clinical development programs and expanding treatment pipelines for rare skeletal disorders, including JMC
• There is an increasing emphasis on combination approaches that integrate pharmacological treatments with supportive care measures, such as physiotherapy and orthopedic interventions, to improve overall patient quality of life
• Regulatory agencies are showing greater flexibility for orphan drug approvals, which is encouraging companies to invest in innovative therapies for rare genetic disorders like JMC
• Telemedicine and digital health platforms are increasingly being used to monitor disease progression, adherence to treatment, and patient-reported outcomes, enhancing personalized care and improving long-term disease management

Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Dynamics

Driver

Rising Awareness and Need for Effective Disease Management

• The increasing awareness of JMC among healthcare professionals, patients, and caregivers is driving demand for more effective treatments and comprehensive disease management solutions
  • For instance, advocacy groups and patient organizations are promoting early diagnosis through genetic testing and skeletal assessments, which facilitates timely intervention and improves treatment outcomes
• The growing prevalence of diagnosed cases, driven in part by improved genetic screening, is leading to higher demand for therapies that can manage symptoms and prevent severe skeletal deformities
• Investments by pharmaceutical companies in research and development of novel therapies for rare bone disorders are expanding the treatment landscape and providing multiple therapeutic options for clinicians and patients
• The rising emphasis on holistic patient care, including pain management, mobility improvement, and growth monitoring, is encouraging adoption of therapies that offer multidimensional benefits
• Government initiatives and funding programs supporting rare disease research are contributing to increased availability of specialized treatments and clinical trial opportunities
• The demand for orphan drugs targeting JMC is also being propelled by growing healthcare budgets in developed regions and enhanced insurance coverage for rare disease treatment
• Increasing education and awareness campaigns for medical professionals regarding rare skeletal disorders are ensuring early identification and referral for specialized care, which supports market growth

Restraint/Challenge

High Treatment Costs, Limited Accessibility, and Research Gaps

• The high cost of advanced therapies for JMC, including targeted pharmacological treatments and biologics, remains a significant barrier to widespread adoption, particularly in developing regions or among patients without comprehensive health coverage
• Limited availability of specialized care centers and trained healthcare professionals for rare skeletal disorders can impede access to timely diagnosis and treatment
• Inadequate awareness and misdiagnosis of JMC in certain regions contribute to delayed interventions, reducing treatment effectiveness and negatively impacting patient outcomes
• Challenges in conducting large-scale clinical trials due to the rarity of JMC slow the pace of drug development and regulatory approval for new therapies
• Research gaps related to long-term safety, efficacy, and disease progression hinder the ability to optimize treatment protocols and personalize therapy for individual patients.
• Regulatory complexities and prolonged approval timelines for orphan drugs in some countries can delay patient access to innovative therapies
• Financial burden associated with lifelong treatment, supportive care, and monitoring may discourage patients or caregivers from seeking consistent treatment
• Overcoming these challenges requires increased investment in rare disease research, expansion of healthcare infrastructure, patient education initiatives, and the development of more affordable therapy options
• Collaborative efforts among pharmaceutical companies, healthcare providers, and patient advocacy groups are essential to improve accessibility, affordability, and awareness for JMC treatment worldwide

Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Scope

The market is segmented on the basis of mutation, bone type, diagnosis, population type, treatment, end user, and distribution channel.

• By Mutation

On the basis of mutation, the Jansen’s Metaphyseal Chondrodysplasia (JMC) market is segmented into PTHR1 Codon 223, PTHR1 Codon 410, and PTHR1 Codon 458. The PTHR1 Codon 223 segment dominated the largest market revenue share of 44.1% in 2024, driven by its higher prevalence in diagnosed cases globally. Patients with this mutation often require frequent monitoring and targeted treatment strategies, which supports sustained market demand. The segment benefits from established clinical protocols and standardized diagnostic practices. Research advancements in understanding the molecular mechanisms of Codon 223 mutations enhance treatment precision. Hospitals and specialty clinics prefer established therapies due to predictable clinical outcomes. Early genetic testing ensures timely diagnosis, increasing treatment uptake. Public and private healthcare programs facilitate access to care. Awareness campaigns for rare bone disorders improve recognition of Codon 223 cases. Insurance coverage in key regions supports treatment affordability. Long-term management and follow-up care reinforce continued market growth. Clinician familiarity with Codon 223 mutation profiles increases prescription confidence. Comprehensive treatment regimens contribute to segment dominance.

The PTHR1 Codon 410 segment is anticipated to witness the fastest CAGR of 18.7% from 2025 to 2032. Increasing identification of Codon 410 mutations through advanced genetic testing drives growth. Clinical research focusing on targeted therapies for Codon 410 improves patient outcomes. Rising awareness among healthcare providers about rare bone disorders supports early diagnosis. Technological advances in molecular diagnostics facilitate detection in both pediatric and adult populations. Urban and semi-urban clinics adopt specialized protocols for managing Codon 410 cases. Government and NGO programs supporting rare disease management further enhance accessibility. Combination therapies and personalized treatment plans increase effectiveness. Patient support programs improve adherence and long-term outcomes. Expansion of specialty clinics in high-income regions accelerates adoption. Clinical trials investigating Codon 410 interventions boost treatment options. Rising publication of epidemiological data highlights unmet needs. Digital health platforms aid monitoring and follow-up care.

• By Bone Type

On the basis of bone type, the Jansen’s Metaphyseal Chondrodysplasia (JMC) market is segmented into Arm Bone, Legs Bone, Facial Bone, and Others. The Legs Bone segment dominated the largest market revenue share of 46.5% in 2024, owing to its frequent involvement in mobility impairment and severe skeletal abnormalities. Patients with legs bone deformities often require surgery and long-term rehabilitation, driving consistent treatment demand. Hospitals and specialty clinics prefer evidence-based treatment protocols for these patients. Early intervention programs reduce long-term complications, enhancing clinical outcomes. Physical therapy and orthopedic management support holistic care. Government health programs for rare skeletal disorders contribute to wider adoption. Research into corrective surgical techniques and minimally invasive interventions strengthens clinician confidence. Pediatric and adult populations are both affected, increasing market size. Insurance coverage improves accessibility to surgery and specialized care. Awareness campaigns for mobility disorders drive patient visits. Repeat treatments for rehabilitation further reinforce market share. Clinical guidelines standardize care and improve patient outcomes.

The Facial Bone segment is expected to witness the fastest CAGR of 19.3% from 2025 to 2032, driven by growing demand for corrective procedures in craniofacial deformities associated with JMC. Advances in surgical techniques and 3D planning technology enhance treatment precision. Cosmetic and functional improvement therapies increase patient adoption. Specialty clinics focusing on craniofacial disorders expand access. Rising awareness among parents and adult patients about early corrective interventions boosts growth. Minimally invasive approaches reduce recovery time, encouraging uptake. Research into biomaterials and reconstructive techniques supports adoption. Telemedicine consultations allow broader geographic reach. Insurance and reimbursement support access to specialized care. Multidisciplinary approaches combining surgery and therapy improve outcomes. Clinical guidelines highlight best practices, fostering adoption. Digital imaging and planning tools accelerate procedural success. Early detection programs facilitate timely intervention, strengthening growth prospects.

• By Diagnosis

On the basis of diagnosis, the Jansen’s Metaphyseal Chondrodysplasia (JMC) market is segmented into Clinical Evaluation, Physical Evaluation, and Specialized Evaluation. The Clinical Evaluation segment dominated the largest market revenue share of 50.2% in 2024, due to its established role as the primary method for initial detection and routine monitoring of JMC cases. Clinicians rely on clinical assessment to identify hallmark skeletal and growth abnormalities. Standardized protocols enable consistent diagnosis across hospitals and clinics. Early detection through clinical evaluation supports timely intervention, reducing long-term complications. Clinical guidelines facilitate accurate evaluation and treatment planning. Hospitals and specialty clinics integrate clinical assessment with imaging and genetic testing. Patient education programs improve recognition of key symptoms. Longitudinal monitoring of growth and skeletal development ensures proper follow-up. Multi-disciplinary care teams enhance treatment outcomes. Clinical evaluation remains cost-effective and widely accessible. Training programs increase clinician proficiency in identifying rare bone disorders. Public awareness initiatives reinforce early clinical assessment.

The Specialized Evaluation segment is expected to witness the fastest CAGR of 20.1% from 2025 to 2032, driven by advances in genetic testing, molecular diagnostics, and imaging techniques. Precision diagnostics allow identification of rare JMC mutations and complex skeletal abnormalities. Early identification enables tailored treatment strategies and personalized care plans. High-income regions adopt specialized evaluation protocols more rapidly. Specialty clinics integrate multidisciplinary approaches combining genetics, radiology, and orthopedics. Research programs and clinical trials benefit from accurate diagnostics. Insurance coverage and government initiatives support accessibility. Digital health platforms enhance patient monitoring and data collection. Clinician training in advanced diagnostics accelerates adoption. Early detection reduces complication rates and improves quality of life. Awareness campaigns emphasize the importance of specialized evaluation. Hospital and clinic infrastructure upgrades facilitate implementation. Technological innovations in imaging and molecular testing expand market opportunities.

• By Population Type

On the basis of population type, the Jansen’s Metaphyseal Chondrodysplasia (JMC) market is segmented into Children and Adults. The Children segment dominated the largest market revenue share of 53.7% in 2024, as pediatric patients represent the majority of diagnosed JMC cases. Early intervention and monitoring are crucial for growth, skeletal development, and prevention of severe deformities. Pediatric care involves multidisciplinary treatment including surgery, medication, and physical therapy. Hospitals and specialty clinics focus on child-specific treatment protocols and long-term follow-up. Early genetic testing enables timely diagnosis and intervention. Parental awareness programs and school health initiatives increase early detection. Pediatric-focused rehabilitation programs enhance functional outcomes. Insurance coverage supports surgical and medication access. Research on pediatric JMC management strengthens clinical practices. NGOs contribute to accessibility in underserved regions. Clinical guidelines prioritize growth monitoring and developmental milestones.

The Adults segment is expected to witness the fastest CAGR of 18.9% from 2025 to 2032, driven by delayed diagnoses and increased identification of adult JMC cases through improved genetic and imaging techniques. Adult patients often require corrective surgeries, pain management, and rehabilitation. Specialty clinics and hospitals provide tailored treatment for functional and cosmetic outcomes. Awareness campaigns among adult patients promote early healthcare-seeking behavior. Technological advances in surgery and therapy enhance treatment efficacy. Insurance coverage and government programs support access to adult-specific interventions. Clinical studies focus on managing complications and chronic symptoms. Rehabilitation programs improve mobility and quality of life. Telemedicine enables follow-up and monitoring for remote patients. Combination therapies increase treatment effectiveness. Multidisciplinary care teams support comprehensive adult management. Advanced diagnostics facilitate precise intervention.

• By Treatment

On the basis of treatment, the Jansen’s Metaphyseal Chondrodysplasia (JMC) market is segmented into Surgery and Medication. The Surgery segment dominated the largest market revenue share of 58.4% in 2024, owing to the high incidence of skeletal deformities requiring corrective procedures. Hospitals and specialty clinics implement standardized surgical protocols to restore mobility and function. Surgical interventions reduce long-term complications and improve patient quality of life. Pediatric patients often undergo staged surgeries to accommodate growth. Reconstructive techniques and 3D planning improve outcomes. Insurance coverage and government support programs enhance accessibility. Surgeons prefer evidence-based procedures with high success rates. Rehabilitation programs complement surgical treatment for optimal recovery. Patient education ensures post-operative compliance. Multidisciplinary teams integrate surgery with medication and therapy. Surgical innovation and minimally invasive techniques reduce recovery time. Repeat interventions are facilitated by long-term monitoring programs.

The Medication segment is expected to witness the fastest CAGR of 17.6% from 2025 to 2032, driven by advancements in pharmacological management for pain, bone growth, and skeletal abnormalities. Targeted medications improve treatment outcomes in both pediatric and adult patients. Hospitals and specialty clinics increasingly prescribe novel drug therapies alongside surgical interventions. Research in molecular medicine supports development of effective medications. Telemedicine and digital adherence programs enhance compliance. Government initiatives and insurance reimbursement improve accessibility. Combination therapies optimize skeletal health and symptom management. Pharmaceutical innovations reduce side effects and improve efficacy. Awareness campaigns support early adoption. Multidisciplinary approaches integrate medication with rehabilitation. Pediatric and adult patient programs facilitate consistent use. Clinical trials accelerate approval of new medications. Improved pharmacological strategies enhance long-term patient outcomes.

• By End User

On the basis of end user, the Jansen’s Metaphyseal Chondrodysplasia (JMC) market is segmented into Hospitals, Specialty Clinics, and Others. The Hospitals segment dominated the largest market revenue share of 56.3% in 2024, as they offer comprehensive care including diagnosis, surgery, medication, and rehabilitation. Hospitals maintain multidisciplinary teams for JMC management, ensuring optimal outcomes. Bulk procurement programs improve drug and surgical supply. Urban and semi-urban hospitals provide specialized care for complex cases. Awareness campaigns in hospitals enhance early detection. Insurance coverage and government initiatives support treatment affordability. Hospitals ensure continuous patient monitoring and follow-up. Pediatric and adult care programs increase adoption. Clinical guidelines reinforce standardized protocols. Repeat interventions and rehabilitation reinforce demand. NGO-supported initiatives improve accessibility. Hospitals remain primary centers for rare bone disorder care.

The Specialty Clinics segment is expected to witness the fastest CAGR of 19.1% from 2025 to 2032, driven by the rise in clinics focusing on rare skeletal disorders. Specialty clinics offer targeted diagnosis, personalized treatment plans, and advanced therapies. Urban expansion and increased patient awareness accelerate adoption. Integration of genetic testing, imaging, and orthopedic care improves outcomes. Telemedicine and remote monitoring enhance accessibility. Insurance and reimbursement policies support adoption. Clinician training in rare disorder management strengthens service delivery. Pediatric and adult patients benefit from specialized protocols. Multidisciplinary approaches ensure comprehensive care. Awareness campaigns promote early detection and intervention. Research and clinical trials conducted at specialty clinics advance treatment innovation. Expansion in high-income regions supports market growth.

• By Distribution Channel

On the basis of distribution channel, the Jansen’s Metaphyseal Chondrodysplasia (JMC) market is segmented into Direct Tender, Retail Sales, and Others. The Direct Tender segment dominated the largest market revenue share of 52.7% in 2024, owing to bulk procurement by hospitals and specialty clinics for surgical instruments, medications, and rehabilitation equipment. Government and NGO programs support centralized tendering to improve supply efficiency. Direct tenders ensure quality control and standardized distribution. Urban and semi-urban healthcare centers benefit from timely availability of treatment resources. Repeat orders and long-term contracts maintain steady supply. Cost-effectiveness and efficiency drive adoption in high-volume centers. Hospitals rely on tenders for essential medications and equipment. Procurement guidelines reinforce compliance. Awareness campaigns support rational use of distributed resources. Specialized clinics and tertiary hospitals prefer centralized tendering. Monitoring and logistics improvements ensure timely delivery. Bulk supply systems enhance market stability.

The Retail Sales segment is expected to witness the fastest CAGR of 21.3% from 2025 to 2032, driven by increased patient preference for convenient access to medications, orthopedic supports, and home rehabilitation equipment. Urban and semi-urban populations increasingly rely on retail pharmacies for fast and reliable procurement. Telemedicine and online prescription integration boost retail adoption. Specialty medications and supportive devices are more accessible through retail channels. Awareness campaigns educate patients about available options. Insurance coverage and private programs improve affordability. Digital platforms support retail pharmacy sales and monitoring. Repeat purchases and chronic management strengthen adoption. Growth in healthcare infrastructure supports retail penetration. Pediatric and adult patients benefit from easier access. Market expansion in developing regions increases reach. Retail pharmacies offer patient counseling and adherence programs. Improved logistics and supply chain integration ensure timely delivery.

Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Regional Analysis

• North America dominated the jansen’s metaphyseal chondrodysplasia (JMC) market with the largest revenue share of 42% in 2024, supported by advanced healthcare infrastructure, high healthcare spending, and the presence of leading pharmaceutical companies specializing in rare disease therapies
• The market remains the primary contributor, with strong growth in the development and deployment of new treatment protocols, clinical trials, and patient support programs for JMC. Rising awareness among healthcare professionals and patients regarding early diagnosis and genetic testing is driving demand for effective therapies
• Increasing availability of specialized treatment centers and access to orphan drugs is enhancing patient outcomes and strengthening market growth in the region. Robust funding for rare disease research, along with government initiatives promoting access to advanced therapies, further supports market expansion

U.S. Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Insight
The U.S. jansen’s metaphyseal chondrodysplasia (JMC) market captured the largest revenue share in 2024 within North America, fueled by increased adoption of targeted therapies and advanced clinical protocols. Clinical research and trials focused on novel therapies, including gene-targeted approaches and pharmacological treatments for bone growth abnormalities, are expanding rapidly. Patient advocacy and education programs are enhancing awareness about early diagnosis, treatment options, and long-term disease management strategies. Investments by pharmaceutical companies in specialized therapies and patient support initiatives are further strengthening the U.S. market.

Europe Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Insight
The Europe jansen’s metaphyseal chondrodysplasia (JMC) market is projected to expand at a substantial CAGR throughout the forecast period, driven by growing awareness of rare skeletal disorders and increasing investments in orphan drug development. The presence of well-established healthcare systems, coupled with access to advanced diagnostics and genetic testing, is facilitating early detection and effective disease management. Collaborative efforts between healthcare providers, pharmaceutical companies, and patient organizations are promoting treatment adoption across residential, pediatric, and specialized care settings. Countries such as Germany, France, and Italy are experiencing notable growth due to supportive regulatory frameworks for rare disease therapies and growing patient access to clinical trials.

U.K. Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Insight
The U.K. jansen’s metaphyseal chondrodysplasia (JMC) market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing awareness of rare skeletal disorders and advancements in treatment protocols. The government and healthcare institutions are promoting early diagnosis and genetic counseling programs, improving access to specialized care. Patient advocacy groups and rare disease networks are supporting education, awareness, and therapy adoption, enhancing market growth in both pediatric and adult populations.

Germany Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Insight
The Germany jansen’s metaphyseal chondrodysplasia (JMC) market is expected to expand at a considerable CAGR during the forecast period, fueled by strong healthcare infrastructure, high-quality diagnostics, and access to innovative therapies. Increasing clinical research initiatives and the presence of pharmaceutical companies focusing on rare skeletal disorders are contributing to market expansion. Awareness campaigns and patient support programs are improving treatment adherence and outcomes, particularly in specialized pediatric care centers.

Asia-Pacific Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Insight
Asia-Pacific jansen’s metaphyseal chondrodysplasia (JMC) market is expected to be the fastest-growing region in the JMC market during the forecast period, driven by increasing healthcare awareness, expanding healthcare infrastructure, and rising investments in rare disease treatment programs. Countries such as India, China, and Southeast Asian nations are witnessing growth in patient access to specialized therapies, genetic testing, and clinical trial participation, accelerating market adoption. The region is seeing increasing government and private initiatives to enhance availability of orphan drugs, improve diagnosis rates, and promote disease-specific patient education. Rising healthcare spending, coupled with improving accessibility to advanced treatment protocols, is supporting sustained market growth.

Japan Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Insight
The Japan jansen’s metaphyseal chondrodysplasia (JMC) market is gaining momentum due to the country’s advanced healthcare system, high awareness of rare diseases, and investments in specialized therapies. Patient access to innovative treatments, including clinical trial participation and targeted pharmacological therapies, is increasing. Collaborative programs between healthcare institutions and research organizations are facilitating early diagnosis and comprehensive disease management.

China Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Insight
The China jansen’s metaphyseal chondrodysplasia (JMC) market accounted for the largest revenue share in Asia-Pacific in 2024, attributed to rapid healthcare modernization, urbanization, and rising awareness of rare skeletal disorders. Growing investment in rare disease treatment programs, expansion of specialized care centers, and increasing patient participation in clinical research are driving market growth. Supportive government policies and initiatives promoting access to orphan drugs and advanced therapies further accelerate market adoption.

Jansen’s Metaphyseal Chondrodysplasia (JMC) Market Share

The Jansen’s Metaphyseal Chondrodysplasia (JMC) industry is primarily led by well-established companies, including:

• Ultragenyx Pharmaceutical Inc. (U.S.)
• BioMarin Pharmaceutical Inc. (U.S.)
• Amryt Pharma (U.K.)
• Alexion Pharmaceuticals (U.S.)
• Sanofi (France)
• Takeda Pharmaceutical Company (Japan)
• Kyowa Kirin Co., Ltd. (Japan)
• Sobi (Sweden)
• Chiesi Farmaceutici (Italy)
• F. Hoffmann-La Roche AG (Switzerland)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• Ipsen (France

Latest Developments in Global Jansen’s Metaphyseal Chondrodysplasia (JMC) Market

• In May 2024, the National Center for Advancing Translational Sciences (NCATS) announced the initiation of a first-in-human Phase 1 clinical trial for Jansen’s Metaphyseal Chondrodysplasia (JMC) at the NIH Clinical Center. This trial is based on a novel investigational drug, Parathyroid Hormone-Inverse Agonist (PTH-IA), which was developed through a collaboration with researchers at Massachusetts General Hospital and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The FDA granted Investigational New Drug (IND) approval for PTH-IA in October 2023, marking a significant milestone in the development of a potential treatment for this ultra-rare bone disease
• In August 2024, the NIH Research Festival featured a presentation on the development of PTH-IA as a new investigational drug for JMC. This peptide-based therapy aims to counteract the constitutive activation of the parathyroid hormone receptor, a hallmark of JMC, by acting as an inverse agonist. The presentation highlighted the progress made in preclinical studies and the upcoming clinical trial to evaluate the safety and efficacy of PTH-IA in humans
• In June 2025, a collaborative study involving institutions such as Massachusetts General Hospital and the University of Wisconsin-Madison published findings on a new mouse model for JMC. This model revealed progressive skeletal deformities and altered mineral ion metabolism, providing insights into the disease mechanisms and potential therapeutic targets. The study, published in the Proceedings of the National Academy of Sciences, underscores the importance of animal models in understanding JMC and developing targeted therapies
• In February 2025, Sequencing.com highlighted advancements in genetic testing for JMC, emphasizing the role of whole-genome sequencing in identifying mutations associated with the disorder. This development aids in early diagnosis and personalized treatment strategies for affected individuals

SKU-60990